Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy.
OBJECTIVE: To report our clinical experience and 5-year prostate-specific antigen (PSA) relapse-free survival rate for early-stage prostate cancer after (125)I low-dose-rate prostate brachytherapy. PATIENTS AND METHODS: In all, 300 patients were treated between March 1999 and April 2003, and follow...
Päätekijät: | Khaksar, S, Laing, R, Henderson, A, Sooriakumaran, P, Lovell, D, Langley, SE |
---|---|
Aineistotyyppi: | Journal article |
Kieli: | English |
Julkaistu: |
2006
|
Samankaltaisia teoksia
-
Urinary morbidity after 125I brachytherapy of the prostate.
Tekijä: Henderson, A, et al.
Julkaistu: (2004) -
Novel prostate brachytherapy technique: improved dosimetric and clinical outcome.
Tekijä: Nobes, J, et al.
Julkaistu: (2008) -
Novel prostate brachytherapy technique: improved dosimetric and clinical outcome.
Tekijä: Nobes, J, et al.
Julkaistu: (2008) -
Brachytherapy: the surgeon's perspective.
Tekijä: Henderson, A, et al.
Julkaistu: (2004) -
Gleason scoring varies among pathologists and this affects clinical risk in patients with prostate cancer.
Tekijä: Sooriakumaran, P, et al.
Julkaistu: (2005)